RESUMO
Hypertension is the main disease in Russian Federation--its frequency is 39.2% in men and 41.1% in women. In recent years course of a disease is accompanied by the metabolic derangements which form the metabolic syndrome. In the basis of pathogenesis of hypertension are insulinresistance and compensatory hyperinsulinemia in combination with associated metabolic derangements. Inveterate insulinresistance leads to hypertension.
Assuntos
Hipertensão/epidemiologia , Hipertensão/fisiopatologia , Síndrome Metabólica/fisiopatologia , Feminino , Humanos , Hipertensão/complicações , Hipertensão/patologia , Masculino , Síndrome Metabólica/complicações , Síndrome Metabólica/epidemiologia , Síndrome Metabólica/patologia , Federação Russa/epidemiologiaRESUMO
The influence of angiotensin II blocker in thrombocytes aggregative capacity in patients with arterial hypertension and metabolic syndrome was assessed. 32 patients were treated with eprosartan during 16 weeks. Dynamics of lipid peroxidation in plasma and thrombocytes, liquid part of blood and platelets antioxidant immunity, thrombocytes aggregative capacity were assessed. The results were processed using Student's test. The use of eprosartan in patients with arterial hypertension and metabolic syndrome has positive influence on peroxidation syndrome and optimizes thrombocytes aggregation.
Assuntos
Acrilatos/uso terapêutico , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Hipertensão/tratamento farmacológico , Imidazóis/uso terapêutico , Síndrome Metabólica/tratamento farmacológico , Agregação Plaquetária/efeitos dos fármacos , Tiofenos/uso terapêutico , Feminino , Seguimentos , Humanos , Hipertensão/sangue , Hipertensão/complicações , Masculino , Síndrome Metabólica/sangue , Síndrome Metabólica/complicações , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
The aim of the study was to evaluate therapeutic effects of losartan on intravascular thrombocyte activity (ITA) in patients suffering from arterial hypertension with metabolic syndrome (MS). The subjects of the study were 35 patients administered losartan 50 mg a day for 4 months. The dynamics of the following parameters were evaluated: anthropometric parameters, blood lipids, lipid peroxidation in blood plasma and thrombocytes, the anti-oxidative protection of the liquid part of blood and platelets, and ITA. Student criterion was used for statistical analysis. In patients with AH and MS losartan had a positive effect on peroxidation syndrome and optimized ITA. To maintain the positive effects, prolonged administration of losartan is needed. In order to lower body mass in AH patients with MS losartan should be used in combination with non-drug means.
